News

Merck and Dr. Reddy seal biosimilar pact
Enlarge image

BusinessGermany

Merck and Dr. Reddy seal biosimilar pact

07.06.2012 - German Merck Serono and India’s Dr. Reddy’s will co-develop copycat cancer antibody drugs that are losing patent protection.

Darmstadt/Hyberabad – German Merck has made its first step into the emerging biosimilars market while it restructures its business to cope with expected revenue losses for some of its biggest selling pharmaceutical products. On 6 June, Merck KGaA and Dr. Reddy’s Laboratories Ltd. announced plans to co-develop a portfolio of biosimilar monoclonal antibodies (mAbs) in oncology. With the deal, Merck Serono, whose dual Geneva-based headquarters is to be shut down due to restructuring, expands its market presence to emerging markets. Dr. Reddy’s can benefit from Merck’s access to the European and US market and the company’s know-how in antibody development.

According to the terms of the agreement, the companies will share their expertises to bring new cheaper formulations of approved antibodies to the market, which have lost patent protection. The Indian generic drug maker, who markets already four biosimilars in India and other emerging markets, brings in its expertise in making biosimilar versions of originator drugs and will lead early product development including Phase I studies. Merck-Serono, the biotech arm of German Merck KGaA, will contribute its know-how in developing, manufacturing, and commercialising biopharmaceuticals and will take responsibility for manufacturing and late clinical development. Commercially, Merck will hold the rights to market any co-developed in all markets outside the US with the exception of several unspecified emerging markets. In the US, where rules for biosimilar market approval are expected to be established this year, both Merck and Dr Reddy’s will co-market co-developed mAbs and will share profits. Dr Reddy’s will receive royalty payments from Merck. The companies said they will fully share R&D costs.

Just recently, the world’s largest antibody contract manufacturing firm Boehringer Ingelheim announced to step into the biosimilar field. All major pharma players have already established biosimilar pipelines, because the copycat versions of antibody blockbusters such as Herceptin, Mabthera can be developed 30% cheaper than the originators. Experts say, however, that market uptake of biosimilars will depend on acceptance of the copycat drugs in the US.

http://www.european-biotechnology-news.com/news/news/2012-02/merck-and-dr-reddy-seal-biosimilar-pact.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ANALYTIK JENA14.00 EUR0.07%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%

FLOP

  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 29.03.2015